Pediatric Bone Sarcomas: Outcome of Multimodality Treatment in a Single Institution in South India over a Decade

Abstract

Context: Pediatric bone sarcoma is a rare entity with low incidence of around 2.5–6 per million population in India. Management of this condition is well standardized, and global survival data are available; however, there is a paucity of data in the Indian perspective. Aim of the Study: The aim of this study is to analyze various prognostic factors and survival outcome. The purpose of this study is to assess the role of surgery, multiagent chemotherapy, and radiation in the management of these tumors. Patients and Methods: Retrospective analysis of patients aged 18 and less, diagnosed as bone sarcomas and treated in our tertiary cancer center. All the patients received at least one form of therapy depending on stage and site of the primary lesion. Results: Twenty-one patients of Ewing sarcoma and 20 patients of osteosarcomas were eligible and were included in the study. In Ewing sarcoma, completing the full course of standard chemotherapy and radiotherapy to the local site was associated with improved survival. In osteosarcoma, limb salvage surgery (LSS) had a significant difference in overall survival compared to amputation. Induction chemotherapy was associated with better percentage of necrosis and showed improved survival. The percentage of necrosis correlated positively with survival which was statistically significant (P = 0.015). Conclusion: The median survival in both these bone sarcomas is inferior to global trends. Probable reasons for such discrepancy are lack of compliance to treatment protocols due to age factors and late presentation. Completion of multiagent chemotherapy in both the tumors add to better survival. Radiotherapy in Ewing sarcoma improves survival. In osteosarcoma, LSS is an oncologically safe alternative to amputation. The percentage of necrosis following chemotherapy in osteosarcoma is a reliable predictor of prognosis.

Keywords

Ewing sarcoma - osteosarcoma - pediatric bone sarcomas

Publication History

Article published online:
24 May 2021

• References

• 1 Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ. et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348: 694-701
• 2 Schuck A, Ahrens S, Paulussen M, Kuhlen M, Könemann S, Rübe C. et al. Local therapy in localized Ewing tumors: Results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys 2003; 55: 168-77
• 3 Burgert Jr. EO, Nesbit ME, Garnsey LA, Gehan EA, Herrmann J, Vietti TJ. et al. Multimodal therapy for the management of nonpelvic, localized Ewing’s sarcoma of bone: Intergroup study IESS-II. J Clin Oncol 1990; 8: 1514-24
• 4 Esiashvili N, Goodman M, Marcus Jr. RB. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance epidemiology and end results data. J Pediatr Hematol Oncol 2008; 30: 425-30
• 5 Available from: http://www.cancer.net/cancer-types/osteosarcoma-childhood/statistics. [Last accessed on 2016 Nov].
• 6 Canter RJ. Chemotherapy: Does neoadjuvant or adjuvant therapy improve outcomes?. Surg Oncol Clin N Am 2016; 25: 861-72